Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/02/2003US20030185883 2-Acetylpyridine
10/02/2003US20030185882 Pharmaceutical compositions containing oxybutynin
10/02/2003US20030185880 Glyburidge composition
10/02/2003US20030185879 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
10/02/2003US20030185878 Process for producing phospholipid-containing drug
10/02/2003US20030185877 Method of producing oily suspensions of water-soluble vitamins
10/02/2003US20030185876 Nutrient formulations
10/02/2003US20030185875 Sustained or controlled drug release
10/02/2003US20030185873 Provides reversible local anesthesia when implanted or injected in a patient, and a non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia
10/02/2003US20030185869 Having lysozyme adsorbed onto or associated with the surface of an active agent
10/02/2003US20030185868 Topically applying a cinnamic acid ester
10/02/2003US20030185864 Preventives or remedies for atopic dermatitis
10/02/2003US20030185861 Containing a fatty acid triglyceride and one or more C14-18 fatty acid glycerides
10/02/2003US20030185851 Tet transactivator system
10/02/2003US20030185839 Local administration of trefoil peptides.
10/02/2003US20030185838 Administration of intestinal trefoil peptides.
10/02/2003US20030185834 Administering an anti-angiogenesis factor to localize in the choroidal neovasculature; administering photosensitizer; photodynamic therapy by irradiating with laser light
10/02/2003US20030185831 Methods of treating cancer using an FPT inhibitor and antineoplastic
10/02/2003US20030185815 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/02/2003US20030185813 Active substance combinations with insecticidal and acaricidal properties
10/02/2003US20030185810 Tumor radiosensitization using gene therapy
10/02/2003US20030185806 Intact cells that express major histocompatibility antigens with a number of common allotypes from a given mammalian species.
10/02/2003US20030185804 Compounds for the photodecontamination of pathogens in blood
10/02/2003US20030185793 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
10/02/2003US20030185789 Lipase inhibiting polymers
10/02/2003US20030185788 Guanidinium moieties that are either contiguous or spaced along a polymeric backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface
10/02/2003US20030185787 Methods and compositions to prevent formation of adhesions in biological tissues
10/02/2003US20030185786 Bis(polyoxyalkylene) fumarate; epidermal permeability barrier function enhancer, amphiregulin expression inhibitor, epidermal hyperproli- feration inhibitor, HB-EGF expression inducing agent, ameliorating agent for aged skin
10/02/2003US20030185778 Polyamine compounds and compositions for use in conjunction with cancer therapy
10/02/2003US20030185772 Alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent.
10/02/2003US20030185766 HFA suspension formulations of an anhydrate
10/02/2003US20030185765 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
10/02/2003US20030185764 i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient; treating asthma
10/02/2003US20030185763 Containing water, a drug and a mixture of microcrystalline cellulose and an alkali metal carboxyalkylcellulose
10/02/2003US20030185761 Buccal, polar and non-polar spray or capsule containing drugs for treating pain
10/02/2003US20030185758 Embolizing a blood vessel by injecting a mixture os polyacrylonitrile, polyvinyl acetate, cellulose acetate butyrate, nitrocellulose, polycarbonate urethane or maleic acid-styrene copolymer; contrast agent and solvent
10/02/2003US20030185704 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
10/02/2003US20030183091 Compositions for improving lipid metabolism
10/02/2003CA2780743A1 Substituted tetracycline compounds
10/02/2003CA2761440A1 Fredericamycin derivatives
10/02/2003CA2756798A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003CA2714873A1 Plasma carboxypeptidase b inhibitors
10/02/2003CA2488161A1 Novel aminobenzamide derivative
10/02/2003CA2484049A1 Imidazoquinoline adjuvants for vaccines
10/02/2003CA2484044A1 Imidazoquinolineamines as adjuvants in hiv dna vaccination
10/02/2003CA2483258A1 .alpha.aed and .beta.aed regulation of nuclear transcription, gene regulation, and/or gene expression
10/02/2003CA2480471A1 A process for the extraction of anthocyanins from black rice and composition thereof
10/02/2003CA2480417A1 Diclofenac sodium oral pharmaceutical
10/02/2003CA2480385A1 Alkoxypyridine derivatives as nitric oxide synthase inhibitors
10/02/2003CA2480384A1 Phenanthridinones as parp inhibitors
10/02/2003CA2480335A1 Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
10/02/2003CA2480302A1 Compositions and methods for treating and preventing necrosis
10/02/2003CA2480219A1 Pharmaceutical compositions comprising a benzofuran derivative and their use for the treatment of attention deficit/hyperactivity disorder
10/02/2003CA2480100A1 Alertness bar
10/02/2003CA2480099A1 Erbb3 based methods and compositions for treating neoplasms
10/02/2003CA2480096A1 Process for producing triterpene derivatives
10/02/2003CA2480032A1 Use of ltb4 antagonists in veterinary medicine
10/02/2003CA2480031A1 Use of tagatose in laxatives
10/02/2003CA2480016A1 Histone deacetylase: novel molecular target of neurotoxicity
10/02/2003CA2480007A1 Topical composition based on ion-exchange resins, in particular for treating erythemas
10/02/2003CA2480005A1 Heat-reversible composition treating hyposalia and asialia
10/02/2003CA2479898A1 Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives
10/02/2003CA2479887A1 Piperidine or 8-aza-bicyclo¬3.2.1|oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
10/02/2003CA2479881A1 Hif hydroxylase inhibitors
10/02/2003CA2479880A1 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003CA2479748A1 Fine particle size pioglitazone
10/02/2003CA2479731A1 Novel compositions and methods in cancer associated with altered expression of tbx21
10/02/2003CA2479727A1 Novel compositions and methods in cancer associated with altered expression of kcnj9
10/02/2003CA2479722A1 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003CA2479719A1 Novel compositions and methods in cancer associated with altered expression of mcm3ap
10/02/2003CA2479718A1 Analgesics for nasal administration
10/02/2003CA2479672A1 Preemptive prophylaxis of migraine
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479555A1 Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients
10/02/2003CA2479530A1 Hiv therapeutic
10/02/2003CA2479383A1 Storage stable eplerenone formulation
10/02/2003CA2479372A1 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
10/02/2003CA2479338A1 Substituted phenylacetic acids
10/02/2003CA2479260A1 Use of sulfoalkyl ether cyclodextrin as a preservative
10/02/2003CA2479259A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003CA2479257A1 Inhibition of cell death responses induced by oxidative stress
10/02/2003CA2479256A1 Phosphate prodrugs of fluorooxindoles
10/02/2003CA2479254A1 Preventive or therapeutic agent for renal disease
10/02/2003CA2479252A1 Sustained release formulation of tramadol
10/02/2003CA2479218A1 Serotonin and catecholamine system segment optimization technology
10/02/2003CA2479214A1 A substance with sedative effect
10/02/2003CA2479150A1 Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
10/02/2003CA2478974A1 Inhalable sustained therapeutic formulations
10/02/2003CA2478913A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
10/02/2003CA2478839A1 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
10/02/2003CA2478330A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/02/2003CA2478063A1 Lymphatic and blood endothelial cell genes
10/02/2003CA2477812A1 A non-selective cation channel in neural cells and methods for treating brain swelling
10/02/2003CA2477771A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
10/02/2003CA2477651A1 Kinase inhibitors
10/02/2003CA2477091A1 1,2-dihydropyrazol-3-ones as cytokine mediators
10/02/2003CA2477088A1 Active agent delivery systems and methods for protecting and administering active agents
10/02/2003CA2476327A1 Method of administering an injectable antibiotic to the ear of an animal
10/02/2003CA2474637A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
10/02/2003CA2451516A1 Agent for preventing or treating diseases caused by enos expression
1 ... 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 5344 ... 7860